Dean J Kereiakes

Summary

Affiliation: University of Cincinnati
Country: USA

Publications

  1. ncbi Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Carl and Edyth Lindner Center for Research and Education, Cincinnati, OH, USA
    Rev Cardiovasc Med 10:72-82. 2009
  2. ncbi A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center, Cincinnati, Ohio, USA
    JACC Cardiovasc Interv 1:248-57. 2008
  3. ncbi Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials
    Dean J Kereiakes
    Heart Center of Greater Cincinnati and the Lindner Center for Research and Education at The Christ Hospital, Ohio Heart and Vascular Center Inc, Cincinnati, Ohio 45219, USA
    J Am Coll Cardiol 48:21-31. 2006
  4. ncbi Therapeutic substitution: guilty until proven innocent
    Dean J Kereiakes
    The Lindner Center for Research and Education/Ohio Heart Health Center, 2123 Auburn Ave, Suite 424, Cincinnati, OH 45219, USA
    Circulation 108:2611-2. 2003
  5. ncbi Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation
    Dean J Kereiakes
    The Lindner Center for Research and Education, 2123 Auburn Avenue, Suite 424, Cincinnati, Ohio 45219, USA
    Circulation 108:III22-7. 2003
  6. ncbi Inflammation as a therapeutic target: a unique role for abciximab
    Dean J Kereiakes
    Ohio State University, The Lindner Center for Research and Education, and The Ohio Heart Health Center, Cincinnati, Ohio 45219, USA
    Am Heart J 146:S1-4. 2003
  7. ncbi Microcirculatory effects of abciximab and eptifibatide: a critical appraisal
    Dean J Kereiakes
    The Lindner Center for Research and Education, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA
    J Invasive Cardiol 15:481-3. 2003
  8. ncbi Usefulness of a cobalt chromium coronary stent alloy
    Dean J Kereiakes
    The Lindner Center Ohio Heart Health Center, Cincinnati, Ohio 45219, USA
    Am J Cardiol 92:463-6. 2003
  9. ncbi Hippocrates revisited: the evidence for drug-eluting stents
    Dean J Kereiakes
    Carl and Edyth Lindner Center for Research and Education, 2123 Auburn Ave, Suite 424, Cincinnati, Ohio 45219, USA
    Circulation 107:3012-4. 2003
  10. ncbi Durable clinical benefit following Sr90 Beta irradiation therapy for in-stent restenosis in high-volume community practice
    John J Young
    The Carl and Edith Lindner Center for Research and Education, the Ohio Heart Health Center and the Christ Hospital, Cincinnati, OH 45219, USA
    J Invasive Cardiol 15:9A-13A. 2003

Collaborators

Detail Information

Publications99

  1. ncbi Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Carl and Edyth Lindner Center for Research and Education, Cincinnati, OH, USA
    Rev Cardiovasc Med 10:72-82. 2009
    ....
  2. ncbi A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center, Cincinnati, Ohio, USA
    JACC Cardiovasc Interv 1:248-57. 2008
    ..g., GuardWire, Medtronic Vascular/FilterWire EZ, Boston Scientific, Natick, Massachusetts) during percutaneous coronary intervention (PCI) of degenerative saphenous vein grafts (SVG)...
  3. ncbi Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials
    Dean J Kereiakes
    Heart Center of Greater Cincinnati and the Lindner Center for Research and Education at The Christ Hospital, Ohio Heart and Vascular Center Inc, Cincinnati, Ohio 45219, USA
    J Am Coll Cardiol 48:21-31. 2006
    ..The purpose of this research was to determine the relative safety and efficacy of multiple (> or =2) overlapping Cypher sirolimus-eluting stents (SES) (Johnson & Johnson, New Brunswick, New Jersey)...
  4. ncbi Therapeutic substitution: guilty until proven innocent
    Dean J Kereiakes
    The Lindner Center for Research and Education/Ohio Heart Health Center, 2123 Auburn Ave, Suite 424, Cincinnati, OH 45219, USA
    Circulation 108:2611-2. 2003
  5. ncbi Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation
    Dean J Kereiakes
    The Lindner Center for Research and Education, 2123 Auburn Avenue, Suite 424, Cincinnati, Ohio 45219, USA
    Circulation 108:III22-7. 2003
    ....
  6. ncbi Inflammation as a therapeutic target: a unique role for abciximab
    Dean J Kereiakes
    Ohio State University, The Lindner Center for Research and Education, and The Ohio Heart Health Center, Cincinnati, Ohio 45219, USA
    Am Heart J 146:S1-4. 2003
    ..Vascular inflammation represents the "final common pathway" for many disease processes and thus represents the "ultimate therapeutic target" for pharmacologic intervention...
  7. ncbi Microcirculatory effects of abciximab and eptifibatide: a critical appraisal
    Dean J Kereiakes
    The Lindner Center for Research and Education, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA
    J Invasive Cardiol 15:481-3. 2003
  8. ncbi Usefulness of a cobalt chromium coronary stent alloy
    Dean J Kereiakes
    The Lindner Center Ohio Heart Health Center, Cincinnati, Ohio 45219, USA
    Am J Cardiol 92:463-6. 2003
    ..7% of patients. This registry establishes the safety and efficacy of this alloy as a coronary stent platform...
  9. ncbi Hippocrates revisited: the evidence for drug-eluting stents
    Dean J Kereiakes
    Carl and Edyth Lindner Center for Research and Education, 2123 Auburn Ave, Suite 424, Cincinnati, Ohio 45219, USA
    Circulation 107:3012-4. 2003
  10. ncbi Durable clinical benefit following Sr90 Beta irradiation therapy for in-stent restenosis in high-volume community practice
    John J Young
    The Carl and Edith Lindner Center for Research and Education, the Ohio Heart Health Center and the Christ Hospital, Cincinnati, OH 45219, USA
    J Invasive Cardiol 15:9A-13A. 2003
    ..Revascularization in follow-up is predominantly due to progressive disease outside the radiated segment and aggressive secondary prevention, especially prolonged anti-platelet therapy, appear critical to long-term procedural success...
  11. ncbi Health care on trial: America's medical malpractice crisis
    Dean J Kereiakes
    The Lindner Center for Research and Education/Ohio Heart Health Center, 2123 Auburn Ave, Suite 424, Cincinnati, Ohio 45219, USA
    Circulation 109:2939-41. 2004
  12. ncbi Successful exclusion of a left main coronary artery aneurysm with a PTFE-covered coronary stent
    John J Young
    The Lindner Center for Research and Education, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA
    J Invasive Cardiol 16:433-4. 2004
  13. ncbi Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center, Lindner Research Center, Cincinnati, Ohio 45219, USA
    JACC Cardiovasc Interv 1:111-21. 2008
    ....
  14. ncbi Medical and Catheter-Based Therapies for Managing Stable Coronary Disease: Lessons From the COURAGE Trial
    Dean J Kereiakes
    Dean J Kereiakes, MD The Christ Hospital Heart and Vascular Center, The Lindner Center, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA
    Curr Treat Options Cardiovasc Med 11:45-53. 2009
    ..Coronary angiography and definition of the coronary anatomy should be performed in patients with stable angina pectoris to help in selecting the optimal treatment strategy...
  15. ncbi Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Lindner Research Center, Cincinnati, OH 45219, USA
    J Invasive Cardiol 20:335-41. 2008
    ..The safety and efficacy of paclitaxel elution from a bioresorbable polymer has not been studied in diabetic patients...
  16. ncbi Specialized centers and systems for heart attack care
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center, The Lindner Research Center, and Ohio State University, Cincinnati, OH 45219, USA
    Am Heart Hosp J 6:14-20. 2008
    ..This article reviews the rationale behind, as well as the issues inherent to, the development of systems of care for STEMI patients...
  17. ncbi The truth and consequences of the COURAGE trial
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center the Lindner Research Center, Cincinnati, Ohio 45219, USA
    J Am Coll Cardiol 50:1598-603. 2007
    ..An in-depth analysis of the COURAGE trial design and execution is provided...
  18. ncbi Clinical guidelines and practice: in search of the truth
    Dean J Kereiakes
    Heart Center of Greater Cincinnati, Cincinnati, Ohio, USA
    J Am Coll Cardiol 48:1129-35; discussion 1136-8. 2006
    ..It is appropriate at this time to briefly review specific aspects of the American College of Cardiology/American Heart Association practice guidelines and the current process of care for acute ischemic heart disease...
  19. ncbi Coil embolization of a circumflex coronary aneurysm at the time of percutaneous coronary stenting
    Dean J Kereiakes
    The Carl and Edyth Lindner Center for Research and Education, The Lindner Center, Cincinnati, Ohio 45219, USA
    Catheter Cardiovasc Interv 67:607-10. 2006
    ..We describe the percutaneous catheter-based approach to coil embolization of a circumflex coronary aneurysm at the time of obtuse marginal branch coronary stent deployment...
  20. ncbi A novel, low-profile filter-wire (Interceptor) embolic protection device during saphenous vein graft stenting
    John J Young
    The Lindner Center for Research and Education and The Ohio Heart Health Center, Cincinnati, Ohio, USA
    Am J Cardiol 95:511-4. 2005
    ..Major adverse cardiovascular events were observed in only 2 patients (7.7%) and angiographic flow grades were improved...
  21. ncbi Stem cells: the chameleon fountain of youth
    Dean J Kereiakes
    Carl and Edyth Lindner Center for Research and Education, and The Ohio Heart Health Center, Cincinnati 45219, USA
    Circulation 107:939-40. 2003
  22. ncbi Successful long-term therapy following saphenous vein-covered stent deployment for atherosclerotic coronary aneurysm
    Dean J Kereiakes
    The Lindner Center for Research and Education, Ohio Heart Health Center, Cincinnati, Ohio 45219, USA
    Catheter Cardiovasc Interv 55:100-4. 2002
    ..Autologous vein-covered stent deployment should be considered in the treatment of symptomatic or progressively enlarging coronary aneurysms...
  23. ncbi Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile
    Dean J Kereiakes
    Lindner Center for Research and Education and Ohio Heart Health Center, Cincinnati, Ohio, USA
    Am J Cardiol 90:628-30. 2002
  24. ncbi The Emperor's clothes: in search of the vulnerable plaque
    Dean J Kereiakes
    Carl and Edyth Lindner Center for Research and Education, Ohio Heart Health Center, Cincinnati, Ohio, USA
    Circulation 107:2076-7. 2003
  25. ncbi Usefulness of stent length in predicting in-stent restenosis (the MULTI-LINK stent trials)
    D Kereiakes
    The Carl and Edith Lindner Center for Research and Education, Cincinnati, Ohio 45219, USA
    Am J Cardiol 86:336-41. 2000
    ..0001), stent length (p = 0.0038), smoking (p = 0.0105). and diabetes (p = 0.0803) as the most important predictors of in-stent restenosis at late (6- to 9-month) angiographic follow-up...
  26. ncbi Combination antiplatelet therapy following brachytherapy with restenting: it ain't over 'til the fat lady sings
    Dean J Kereiakes
    The Lindner Center for Research and Education/Ohio Heart Health Center, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA
    J Invasive Cardiol 14:115-7. 2002
  27. ncbi Prophylactic abciximab in elective coronary stenting: results of a randomized trial
    Corrado Tamburino
    The Lindner Center for Research and Education, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA
    J Invasive Cardiol 14:72-9. 2002
    ..We characterized patients undergoing elective implantation of long or multiple overlapping coronary stents and determined the impact of abciximab administration on clinical and angiographic outcomes...
  28. ncbi Intragraft verapamil: an ounce of prevention is worth a pound of cure
    Dean J Kereiakes
    Linder Center for Research and Education and Ohio Heart Health Center, USA
    J Invasive Cardiol 14:303-4. 2002
  29. ncbi Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention
    D J Kereiakes
    The Carl and Edyth Lindner Center for Research and Education, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219 USA
    J Invasive Cardiol 13:272-8. 2001
    ..Additional studies may be required to establish the relative safety and efficacy of this new adjunctive pharmacologic strategy when compared with the combination of low-dose, weight-adjusted unfractionated heparin and abciximab...
  30. ncbi Dalteparin in combination with abciximab during percutaneous coronary intervention
    D J Kereiakes
    Carl and Edyth Lindner Center for Research and Education and the Ohio Heart Health Center, 2123 Auburn Ave, Suite 424, Cincinnati, OH 45219, USA
    Am Heart J 141:348-52. 2001
    ..The purpose of this study was to assess anticoagulant effect and clinical safety for several dose regimens of dalteparin administered in combination with abciximab during percutaneous coronary intervention (PCI)...
  31. ncbi Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus
    Dean J Kereiakes
    Lindner Center for Research and Education and The Ohio Heart Health Center, Cincinnati, Ohio 45219, USA
    Am Heart J 144:615-24. 2002
    ....
  32. ncbi The fire that burns within: C-reactive protein
    Dean J Kereiakes
    Carl and Edyth Lindner Center for Research and Education, Ohio Heart Health Center, Cincinnati 45219, USA
    Circulation 107:373-4. 2003
  33. ncbi Platelet GP IIb/IIIa inhibition in unstable angina and non-ST segment elevation MI: application of the ACC/AHA guidelines
    John J Young
    The Lindner Center for Research Education, 2123 Auburn Ave, Suite 424, Cincinnati, OH 45219, USA
    J Invasive Cardiol 15:102-7; quiz 108. 2003
  34. ncbi Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban
    D J Kereiakes
    The Carl and Edyth Lindner Center for Research and Education, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA
    J Thromb Thrombolysis 12:123-7. 2001
    ..Enhanced GP IIb/IIIa binding and inhibition of platelet aggregation for eptifibatide secondary to citrate induced reduction of ionized plasma calcium concentrations has been reported...
  35. ncbi Peri-infarct pacing with CRT in the early postinfarct phase to attenuate long-term remodeling
    Eugene S Chung
    The Christ Hospital Heart and Vascular Center, The Ohio Heart and Vascular Center, The Lindner Center, Cincinnati, OH, USA
    J Cardiovasc Transl Res 2:126-9. 2009
    ..MENDMI will help to determine whether chronic application of peri-infarct pacing provides structural and clinical benefits and will help in the design of further investigations to modify postinfarction ventricular remodeling...
  36. ncbi A guide to drug use during percutaneous coronary intervention
    Joseph K Choo
    The Lindner Center for Research and Education, Cincinnati, Ohio 45219, USA
    Drugs 62:2589-601. 2002
    ....
  37. ncbi Pharmacologic reperfusion strategies for the treatment of ST-segment elevation myocardial infarction
    John J Young
    Lindner Center for Research and Education, Ohio Heart Health Center, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 4:216-27. 2003
    ..This review focuses on the evolving pharmacologic treatment strategies for STEMI...
  38. ncbi Microvolt T-wave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter-defibrillator therapy
    Theodore Chow
    The Lindner Clinical Trial Center at the Christ Hospital and the Ohio Heart and Vascular Center, Cincinnati, Ohio, USA
    J Am Coll Cardiol 49:50-8. 2007
    ....
  39. ncbi Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio 45219, USA
    Am J Cardiovasc Drugs 10:239-46. 2010
    ..The aim of this study was to analyze the magnitude of SBP reductions and the achievement of individual SBP targets in the original BENIFORCE study...
  40. ncbi Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel
    J Emilio Exaire
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Catheter Cardiovasc Interv 64:369-72. 2005
    ..While minor and major TIMI bleeding remained very low in both groups, CD was associated with a twofold increase in risk of any-bleeding event when compared to MC, especially when using GP IIb/IIIa inhibitors...
  41. ncbi Early revascularization and ACC/AHA guideline-compliant medical management improve left ventricular function and short-term prognosis in patients presenting with acute myocardial infarction and severe left ventricular dysfunction
    John J Young
    The Ohio Heart and Vascular Center, The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, USA
    J Invasive Cardiol 18:540-3. 2006
    ..We sought to determine the impact of contemporary treatment strategies on LV function and prognosis in patients with MI and severe LV dysfunction...
  42. ncbi Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)
    A Michael Lincoff
    Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 93:1092-6. 2004
    ..52). This trial represents the largest prospective dataset of bivalirudin administered concomitantly with planned GP IIb/IIIa blockade and provides evidence of the safety and efficacy of this combined antithrombotic approach...
  43. ncbi Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center the Lindner Research Center, 2123 Auburn Avenue, Cincinnati, OH 45219, USA
    J Clin Hypertens (Greenwich) 14:149-57. 2012
    ..6/100.7 mm Hg (baseline BP at randomization) to 125.0 to 136.8 mm Hg/77.8 to 82.5 mm Hg, depending on treatment. Long-term treatment with OM/AML/HCTZ was well tolerated and effective with no new safety concerns...
  44. ncbi Comparison of ultrafiltration, nesiritide, and usual care in acute decompensated heart failure
    Cheryl Bartone
    Heart Center of Greater Cincinnati at The Christ Hospital and The Ohio Heart and Vascular Center, Cincinnati, OH, USA
    Congest Heart Fail 14:298-301. 2008
    ..These findings, as well as the effects on renal function and length of stay, need to be further evaluated in a prospective randomized study...
  45. ncbi Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center the Lindner Research Center, 2123 Auburn Avenue, Cincinnati, OH 45129, USA
    JACC Cardiovasc Interv 3:1229-39. 2010
    ..We evaluated outcomes following XIENCE V everolimus-eluting stent (EES) compared with the Taxus Express(2) paclitaxel-eluting stent (PES) in patients undergoing multilesion and multivessel intervention...
  46. ncbi Platelet activation and progression to complications
    Dean J Kereiakes
    Heart Center of Greater Cincinnati and Lindner Center at Christ Hospital, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 7:75-81. 2006
    ..In general, optimal periprocedural outcomes require high levels of platelet inhibition. Combined administration of antiplatelet therapies may produce additive or synergistic inhibition of platelet-mediated thrombosis...
  47. ncbi Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring
    Dean J Kereiakes
    The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA
    Ther Adv Cardiovasc Dis 4:285-93. 2010
    ..Secondary, prespecified analysis of a single-arm, open-label study evaluating the efficacy of olmesartan medoxomil (OM) plus hydrochlorothiazide (HCTZ) in patients with hypertension and type 2 diabetes...
  48. ncbi Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?
    John J Young
    The Carl and Edyth Lindner Center for Research and Education, Cincinnati, OH 45219, USA
    J Invasive Cardiol 14:404-10. 2002
    ..Evidence in support of the presence, magnitude and possible mechanisms for abciximab survival advantage is herein reviewed...
  49. ncbi The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center and the Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, OH, USA
    J Clin Hypertens (Greenwich) 11:411-21. 2009
    ..2%), and headache (1.1%), were observed in 11.8% of patients. An OM-based treatment algorithm effectively lowers BP in an elderly patient population throughout the 24-hour dosing interval without compromising tolerability...
  50. ncbi Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice
    John J Young
    Carl and Edyth Lindner Center for Research and Education, Ohio Heart Health Center, Cincinnati, Ohio, USA
    J Interv Cardiol 15:115-20. 2002
  51. ncbi Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS
    Dean J Kereiakes
    The Lindner Center for Research and Education, Ohio State University, Cincinnati, USA
    J Invasive Cardiol 15:536-53. 2003
  52. ncbi Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function
    Dean J Kereiakes
    Heart Center of Greater Cincinnati, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 7:S3-11. 2006
    ....
  53. ncbi Propensity-matched patient-level comparison of the TAXUS Liberté and TAXUS element (ION) paclitaxel-eluting stents
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, USA
    Am J Cardiol 108:828-37. 2011
    ..Stent platform-related variables may influence clinical outcomes after drug-eluting stent use despite similar polymer and drug elution. Differences in adjunctive pharmacotherapy and/or stenting technique may also be contributory...
  54. ncbi Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center at the Christ Hospital, Cincinnati, OH, USA
    Cardiovasc Diabetol 11:134. 2012
    ..Patients with hypertension and cardiovascular disease (CVD), diabetes, or chronic kidney disease (CKD) usually require two or more antihypertensive agents to achieve blood pressure (BP) goals...
  55. ncbi Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, OH 45219, USA
    EuroIntervention 8:187-95. 2012
    ..This analysis assesses the incidence of longitudinal stent deformation in three stent platforms...
  56. ncbi New drug-eluting stent platforms to prevent stent thrombosis
    Dean J Kereiakes
    Heart Center of Greater Cincinnati and Lindner Center at Christ Hospital, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 8:S34-43. 2007
    ....
  57. ncbi Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXU
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio 45219, USA
    J Am Coll Cardiol 56:264-71. 2010
    ....
  58. ncbi Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Carl and Edyth Lindner Center for Research and Education, Cincinnati, OH 45219, USA
    Drugs R D 11:251-7. 2011
    ..1%. Conclusions: An olmesartan medoxomil ± HCTZ treatment regimen significantly reduced BP from baseline in patients with hypertension and type 2 diabetes. Clinical Trials Registration: ClinicalTrials.gov identifier: NCT00403481...
  59. ncbi Ischemia is the critical determinant of revascularization benefit: an interventionalist's perspective of the COURAGE trial
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center, Cincinnati, OH, USA
    Rev Cardiovasc Med 10:S45-52. 2009
    ..The evolution of both PCI technology (DES) and adjunctive pharmacology has improved the relative magnitude and durability of PCI benefit compared with medical therapy alone...
  60. ncbi Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality
    Vivek Rajagopal
    The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 94:190-2. 2004
    ....
  61. ncbi Regionalization of care for acute ischemic heart disease: a call for specialized centers
    Eric J Topol
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 107:1463-6. 2003
  62. ncbi Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Lindner Research Center, Cincinnati, Ohio 45219, USA
    EuroIntervention 7:74-83. 2011
    ....
  63. ncbi Thrombosis and drug-eluting stents: a critical appraisal
    Dean J Kereiakes
    Lindner Center for Research and Education, Ohio Heart Health Center, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 5:9-15. 2004
    ..Cumulative data for the Cypher stent do not suggest a propensity for thrombosis, but several caveats should be observed to enhance the safety of the device...
  64. ncbi Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy
    Theodore Chow
    The Lindner Clinical Trial Center at the Christ Hospital and the Ohio Heart and Vascular Center, Cincinnati, Ohio, USA
    J Am Coll Cardiol 47:1820-7. 2006
    ..08 [1.18 to 3.66]; p = 0.01). CONCLUSIONS: Microvolt T-wave alternans is a strong and independent predictor of all-cause and arrhythmic mortality in patients with ischemic cardiomyopathy...
  65. ncbi Contemporary issues in the cath lab. Introduction
    Dean J Kereiakes
    Heart Center of Greater Cincinnati, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 7:S1-2. 2006
  66. ncbi Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center and the Lindner Research Center, Cincinnati, Ohio 45219, USA
    Am J Cardiovasc Drugs 7:361-72. 2007
    ..Accordingly, combinations of two drugs with different mechanisms of antihypertensive action are widely used...
  67. ncbi Interpreting the COURAGE trial. PCI is no better than medical therapy for stable angina? Seeing is not believing
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center, The Lindner Research Center, Cincinnati, OH 45219, USA
    Cleve Clin J Med 74:637-8, 640-2. 2007
  68. ncbi Vascular brachytherapy boon or bust?
    Dean J Kereiakes
    Carl and Edyth Lindner Center for Research and Education, 2123 Auburn Ave, Suite 424, Cincinnati, Ohio 45219, USA
    Circulation 108:389-90. 2003
  69. ncbi Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results
    Dean J Kereiakes
    The Lindner Center for Research and Education, 2123 Auburn Ave, Suite 424, Cincinnati, Ohio 45219, USA
    Circulation 108:1310-5. 2003
    ..These data can be used in phase II efficacy trials of MLu PT for the treatment of coronary atherosclerosis or vulnerable plaque...
  70. ncbi Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study)
    Michael R Tamberella
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA, USA
    Am J Cardiol 89:1429-31. 2002
  71. ncbi Coronary small-vessel stenting in the era of drug elution
    Dean J Kereiakes
    Lindner Center for Research and Education, Ohio Heart Health Center, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 5:S34-45. 2004
    ..DES specifically designed for small-vessel application will become the standard for small vessel PCI...
  72. ncbi Complex coronary intervention in the drug-eluting stent era. Introduction
    Dean J Kereiakes
    Lindner Center for Research and Education, Ohio Heart and Vascular Center, Inc, Christ Hospital, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 6:S1-2. 2005
  73. ncbi Percutaneous coronary revascularization of diabetic patients in the era of drug-eluting stents
    Dean J Kereiakes
    Lindner Center for Research and Education, Ohio Heart and Vascular Center, Inc, Christ Hospital, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 6:S48-58. 2005
    ..Nevertheless, continued improvement in DES delivery as well as optimal adjunctive pharmacotherapy and control of hyperglycemia will be required to achieve the best clinical outcomes following PCI with DES in patients with diabetes...
  74. ncbi Adjunctive antiplatelet therapy during rescue PCI
    John J Young
    Ohio Heart and Vascular Center, The Lindner Center, Christ Hospital, Cincinnati, Ohio, USA
    J Invasive Cardiol 18:63-4. 2006
  75. ncbi US health care: entitlement or privilege?
    Dean J Kereiakes
    The Lindner Center for Research and Education Ohio Heart Health Center, 2123 Auburn Ave, Suite 424, Cincinnati, Ohio 45219, USA
    Circulation 109:1460-2. 2004
  76. ncbi Safety and tolerability of serial home infusions of nesiritide for advanced heart failure
    Eugene S Chung
    The Lindner Clinical Trial Center, The Christ Hospital, Cincinnati, Ohio, USA
    Am J Cardiol 97:1370-3. 2006
    ..In conclusion, serial home infusions of nesiritide in patients with advanced HF appear to be safe and well tolerated, but the efficacy of this therapeutic strategy requires definition in a larger, randomized trial...
  77. ncbi Safety and efficacy of drug-eluting stents
    David O Williams
    Department of Cardiology, Rhode Island Hospital, Providence, Rhode Island, USA
    Rev Cardiovasc Med 6:S22-30. 2005
    ..In addition, specific patient subsets, including those patients with multivessel coronary disease, will be evaluated...
  78. ncbi Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 292:696-703. 2004
    ....
  79. ncbi Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial
    Alexandra J Lansky
    Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, 55 E 59th St, 6th Floor, New York, NY 10022 1112, USA
    Circulation 109:1948-54. 2004
    ..The DELIVER trial was a prospective, randomized, blinded, multicenter clinical evaluation of the non-polymer-based paclitaxel-coated ACHIEVE stent compared with the stainless steel Multi-Link (ML) PENTA stent...
  80. ncbi Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention
    Mark I Furman
    Center for Platelet Function Studies and Division of Cardiovascular Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Am Heart J 145:e6. 2003
    ....
  81. ncbi Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Invasive Cardiol 19:404-9. 2007
    ..We sought to ascertain and compare 12-month target vessel revascularization (TVR) rates for sirolimus-eluting Cyphertrade mark stents and bare-metal stents (BMS) when utilized to treat stenoses in diseased SVGs...
  82. ncbi Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery
    Jeffrey W Moses
    Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute of New York, New York 10021, USA
    N Engl J Med 349:1315-23. 2003
    ..Preliminary reports of studies involving simple coronary lesions indicate that a sirolimus-eluting stent significantly reduces the risk of restenosis after percutaneous coronary revascularization...
  83. ncbi Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial
    Jacqueline Saw
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 108:921-4. 2003
    ....
  84. ncbi Platelet glycoprotein IIb/IIIa inhibition and atheroembolism during bypass graft angioplasty: a cup half full
    Dean J Kereiakes
    Circulation 106:2994-6. 2002
  85. ncbi Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization
    Eric J Topol
    Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Med 113:1-6. 2002
    ..Brief intervention with this monoclonal antibody during percutaneous coronary revascularization is associated with significant improvement of long-term survival...
  86. ncbi Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial
    A Michael Lincoff
    Department of Cardiovascular Medicine, Desk F25, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    JAMA 289:853-63. 2003
    ....
  87. ncbi Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Am Coll Cardiol 45:1932-8. 2005
    ....
  88. ncbi Coronary stent restenosis in patients treated with cilostazol
    John S Douglas
    Emory University School of Medicine, Atlanta, GA, USA
    Circulation 112:2826-32. 2005
    ..We undertook a randomized, double-blind, placebo-controlled trial to determine whether cilostazol, a drug that suppresses intimal proliferation, would reduce renarrowing in patients after stent implantation in native coronary arteries...
  89. ncbi Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1
    Jerrold H Levy
    Cardiothoracic Anesthesiology and Critical Care, Emory University Hospital, Atlanta, Georgia 30322, USA
    Anesth Analg 105:918-25, table of contents. 2007
    ..In this randomized, double-blind, placebo-controlled multicenter trial we evaluated the efficacy and tolerability of clevidipine in treating preoperative hypertension...
  90. ncbi Thrombosis and drug-eluting stents: an objective appraisal
    David R Holmes
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55955, USA
    J Am Coll Cardiol 50:109-18. 2007
    ....
  91. ncbi Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study
    Robert M Mentzer
    Wayne State University School of Medicine, 540 East Canfield, 1241 Scott Hall, Detroit, MI 48201, USA
    Ann Thorac Surg 85:1261-70. 2008
    ..The premise was that inhibition of NHE-1 limits intracellcular Na accumulation and thereby limits Na/Ca-exchanger-mediated calcium overload to reduce infarct size...
  92. ncbi A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study
    Mitchell W Krucoff
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 51:1543-52. 2008
    ....
  93. ncbi Clinical challenges in the prevention and treatment of late and very late stent thrombosis. Introduction
    John J Young
    Swedish Heart and Vascular Institute, Seattle, Washington, USA
    Rev Cardiovasc Med 8:S1-2. 2007
  94. ncbi Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial
    Giora Weisz
    Cardiovascular Research Foundation and Columbia University Medical Center, New York, New York 10032, USA
    J Am Coll Cardiol 47:1350-5. 2006
    ....
  95. ncbi Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists
    Wojciech Mazur
    Baylor College of Medicine and The Methodist Hospital, Houston, Tex, USA
    Am Heart J 143:594-601. 2002
    ..However, patients in whom high-risk features are present after stent placement are at increased risk of ischemic cardiac events even with abciximab treatment...
  96. ncbi Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial
    Gregg W Stone
    Department of Cardiology, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10032, USA
    JAMA 295:1253-63. 2006
    ..The effectiveness of drug-eluting stents in this setting has not been established...
  97. ncbi Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial
    Adam B Greenbaum
    Henry Ford Heart and Vascular Institute, Detroit, MI, USA
    Am Heart J 151:689.e1-689.e10. 2006
    ..The primary aims of this study were to assess the initial safety and pharmacodynamics of cangrelor in patients undergoing PCI...
  98. ncbi Impact of coronary culprit lesion calcium in patients undergoing paclitaxel-eluting stent implantation (a TAXUS-IV sub study)
    Issam Moussa
    Cardiovascular Research Foundation and Columbia University Medical Center, New York, NY, USA
    Am J Cardiol 96:1242-7. 2005
    ..30 and 0.26, respectively). In conclusion, implantation of paclitaxel-eluting stents in patients with de novo coronary lesions significantly reduced restenosis in patients with and without calcified lesions...
  99. ncbi The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients
    Solomon Aronson
    Department of Anesthesiology, Duke University Medical Center, Duke South, Room 102 Baker House, Durham, NC 27710, USA
    Anesth Analg 107:1110-21. 2008
    ....